share_log

Shattuck Labs | 8-K: S hattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K: S hattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K：S hattuck Labs公佈2024年第二季度財務業績和近期業務亮點
美股SEC公告 ·  2024/08/01 13:21

Moomoo AI 已提取核心訊息

Shattuck Labs reported Q2 2024 financial results and clinical progress. The company's cash position stood at $105.3M as of June 30, 2024, with projected runway into 2026. Q2 net loss was $21.5M ($0.42 per share), compared to $21.3M ($0.50 per share) in Q2 2023. R&D expenses increased to $19.2M from $18.2M year-over-year.The company announced positive interim data from its Phase 1B trial of SL-172154 combined with Azacitidine in HR-MDS and TP53m AML patients. The HR-MDS cohort showed a 67% objective response rate and 58% complete remission rate, while the TP53m AML cohort achieved a 43% objective response rate. The FDA granted Orphan Drug Designation for SL-172154 in AML treatment.Enrollment is ongoing in the randomized, controlled Phase 1B dose-expansion cohort for frontline HR-MDS patients, with approximately 60 patients being randomized across three treatment arms. In the PROC trial, four of 21 patients achieved partial responses with SL-172154 plus PLD combination as of April 2024.
Shattuck Labs reported Q2 2024 financial results and clinical progress. The company's cash position stood at $105.3M as of June 30, 2024, with projected runway into 2026. Q2 net loss was $21.5M ($0.42 per share), compared to $21.3M ($0.50 per share) in Q2 2023. R&D expenses increased to $19.2M from $18.2M year-over-year.The company announced positive interim data from its Phase 1B trial of SL-172154 combined with Azacitidine in HR-MDS and TP53m AML patients. The HR-MDS cohort showed a 67% objective response rate and 58% complete remission rate, while the TP53m AML cohort achieved a 43% objective response rate. The FDA granted Orphan Drug Designation for SL-172154 in AML treatment.Enrollment is ongoing in the randomized, controlled Phase 1B dose-expansion cohort for frontline HR-MDS patients, with approximately 60 patients being randomized across three treatment arms. In the PROC trial, four of 21 patients achieved partial responses with SL-172154 plus PLD combination as of April 2024.
Shattuck Labs公佈了2024年第二季度的財務業績和臨牀進展。截止到2024年6月30日，公司的現金狀況爲10530萬美元，預計可持續到2026年。2024年第二季度淨虧損爲2150萬美元（每股0.42美元），相比2023年第二季度的2130萬美元（每股0.50美元）有所增加。研發費用同比增長至1920萬美元，去年爲1820萬美元。公司宣佈了其針對HR-MDS和TP5300萬AML患者的SL-172154與阿扎胞苷聯合使用的10億階段試驗的積極中期數據。HR-MDS組顯示67%的客觀反應率和58%的完全緩解率，而TP5300萬AML組達成了43%的客觀反應率。FDA已授予SL-172...展開全部
Shattuck Labs公佈了2024年第二季度的財務業績和臨牀進展。截止到2024年6月30日，公司的現金狀況爲10530萬美元，預計可持續到2026年。2024年第二季度淨虧損爲2150萬美元（每股0.42美元），相比2023年第二季度的2130萬美元（每股0.50美元）有所增加。研發費用同比增長至1920萬美元，去年爲1820萬美元。公司宣佈了其針對HR-MDS和TP5300萬AML患者的SL-172154與阿扎胞苷聯合使用的10億階段試驗的積極中期數據。HR-MDS組顯示67%的客觀反應率和58%的完全緩解率，而TP5300萬AML組達成了43%的客觀反應率。FDA已授予SL-172154在AML治療中的孤兒藥設計ation。在針對一線HR-MDS患者的隨機對照10億劑量擴展組中，招生仍在進行，約60名患者在三個治療組中被隨機分配。在PROC試驗中，截至2024年4月，21名患者中有4名在SL-172154與PLD組合治療下取得了部分反應。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間